Prostate-specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.
Daniel W KimMing-Hui ChenJing WuHartwig HulandMarkus GraefenDerya TilkiAnthony V D'AmicoPublished in: Cancer (2021)
Some men with PSA ≤ 4 ng/mL and a biopsy GS of 9 to 10 may have pathologic or genetic variants that make them less amenable to a cure with current standards of care. Additional workup assessing for small cell, neuroendocrine, and genetic variants should be considered.
Keyphrases
- prostate cancer
- radical prostatectomy
- ultrasound guided
- fine needle aspiration
- middle aged
- healthcare
- single cell
- palliative care
- cardiovascular events
- neoadjuvant chemotherapy
- cell therapy
- quality improvement
- risk factors
- type diabetes
- squamous cell carcinoma
- cardiovascular disease
- locally advanced
- stem cells
- radiation therapy
- lymph node
- bone marrow
- affordable care act